Business Wire

IN-BOEHRINGER-INGELHEIM

7.12.2022 10:40:38 CET | Business Wire | Press release

Share
Phase III trial demonstrated Jardiance is the first SGLT2 inhibitor to show statistically significant reduction in blood sugar levels in children and adolescents with type 2 diabetes

The DINAMO Phase III clinical trial met its primary endpoint by demonstrating a statistically significant reduction in HbA1c (a marker of average blood sugar) with empagliflozin compared with placebo for children and adolescents aged 10-17 years living with type 2 diabetes.1 When empagliflozin was added to other baseline treatments (diet, exercise, metformin and/or insulin) HbA1c was reduced by 0.84% compared with placebo at week 26 (95% CI –1.50 to –0.19; P=0.012).1 The results were presented today at the International Diabetes Federation (IDF) World Diabetes congress 20221, Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced.1

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221207005405/en/

The DINAMO (DIabetes study of liNAgliptin and eMpagliflozin in children and adOlescents) trial included youth aged 10-17 years with type 2 diabetes and HbA1c ≥6.5% and ≤10.5%. Participants were randomly assigned treatment with empagliflozin (10 or 25 mg) (n=52), linagliptin (5 mg) (n=53) or placebo (n=53) once daily. All participants were treated with diet and exercise plus, when appropriate, metformin and/or insulin.1

The overall safety data was generally consistent with previous findings in adults with type 2 diabetes, confirming the well-established safety profile of both Jardiance® (empagliflozin) and Trajenta® (linagliptin).1

“Across the lifespan, we know that people living with type 2 diabetes have a high risk for many diabetes complications, so it’s important to recognize and treat diabetes early in its course,” said Lori Laffel, M.D., Principal Investigator of the DINAMO study and Chief of the Pediatric, Adolescent, and Young Adult Section at the Joslin Diabetes Center and Professor of Pediatrics at Harvard Medical School. “Today’s results from the DINAMO global clinical trial demonstrated that the SGLT2 inhibitor empagliflozin compared with placebo significantly improved overall blood sugar control in children and adolescents with type 2 diabetes. These findings are particularly important given the need for more therapeutic options, especially oral agents, to manage type 2 diabetes in young people as, to date, metformin is the only globally available oral treatment for youth.”

A secondary endpoint from the trial showed that at week 26, empagliflozin reduced fasting plasma glucose (–35.2 mg/dL; P=0.0035).1

“With more than 41,000 new cases worldwide annually, type 2 diabetes in today’s young people is a global public health issue, especially in light of rise of risk factors such as obesity,” said Lykke Hinsch Gylvin, M.D., Chief Medical Officer at Boehringer Ingelheim. “The clinically meaningful benefit and consistent safety profile demonstrated with empagliflozin in the DINAMO trial is an encouraging outcome for the vulnerable population of children and adolescents.”

“The rise in the prevalence of type 2 diabetes in the pediatric population highlights a clear unmet need,” said Jeff Emmick, M.D., Ph.D., Vice President, Product Development, Eli Lilly & Company. “Having overcome the challenges in recruitment and design that pediatric trials tend to face, the outcomes of DINAMO represent another positive step forward in Boehringer Ingelheim and Lilly’s commitment to improve the lives of people living with cardio-renal and metabolic conditions such as type 2 diabetes.”

Reduction in HbA1c in participants treated with linagliptin was not statistically significant when compared with placebo. A numerical reduction of 0.34% (P=0.2935) was observed.1

The findings have been submitted for publication in a peer-reviewed journal.

Please click on the below link for further ‘Notes to editors’ and ‘References’:

https://www.boehringer-ingelheim.com/human-health/metabolic-diseases/diabetes/new-positive-data-phase-iii-type-2-diabetes-trial

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221207005405/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Komainu Completes Two-Way Digital Asset Transfers for First Abu Dhabi Bank as Institutional Custody Framework Goes Live3.11.2026 10:30:00 CET | Press release

Komainu, a regulated digital asset services provider and custodian backed by Laser Digital and Blockstream, has completed the two-way transfer of a portfolio of digital assets with First Abu Dhabi Bank (FAB) through the institutional digital asset custody framework the two firms have established. The transfers settled instantly. The milestone marks the operationalisation of Komainu’s collaboration with FAB Global Markets, integrating regulated digital asset custody and connectivity capabilities with FAB’s existing infrastructure. The transfers demonstrate the bank’s ability to move digital assets both into and out of the custody environment, validating the infrastructure required to support institutional digital asset activity. The framework has also been designed to support future institutional financing solutions, including lending backed by digital assets held in regulated custody. This provides a foundation for FAB to further integrate digital assets into its financial markets infr

Klarna Expands Partnership With Mollie, Bringing Enhanced Dispute Management and Consumer FX to Merchants Across Europe3.11.2026 10:00:00 CET | Press release

Klarna, the everyday finance network, announced today an expanded agreement with Mollie, one of Europe’s leading payment service providers. Building on their existing partnership, the new contract brings additional Klarna capabilities, including enhanced dispute management and consumer FX, to Mollie’s more than 350,000 merchants. The new features will roll out across all Mollie’s integrations, via direct API, hosted payment page and via their extensive Platform partner plug in ecosystem. Merchants already offering Klarna through Mollie will gain access to these features through their existing integration. Merchants new to Klarna can offer Pay in Full, Pay in 3 interest-free installments and Financing at checkout, and can enable it within minutes. With Mollie’s recent acquisition of GoCardless and coverage across all EEA markets, the expanded agreement extends Klarna’s reach and product offering across the region. “This deepened agreement with Mollie opens up Klarna to merchants across

Bizzmine Unveils More Than 40 Quality, EHS and Compliance Solutions Alongside Major Advances in AI and User Experience3.11.2026 09:47:00 CET | Press release

At Bizzmine’s Digital Summit 2026 they showcased a comprehensive solution portfolio, AI agents working within business processes, a modern experience across devices and the next stage of Bizzmine’s AI strategy. Bizzmine has announced a major expansion of its intelligent QHSE platform at Digital Summit 2026. The company presented more than 40 ready to use solutions spanning Quality, Environment, Health and Safety (EHS) and Compliance, together with advances in artificial intelligence and a fundamentally renewed user experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261102147396/en/ Bizzmine summit panel discussion The latest developments give organisations a broader range of operational processes to manage in one environment, with connected information, common governance and a clear view of responsibilities and completed work across locations. “What impresses me most is how quickly we can now turn innovation into val

Hightouch Launches Match Booster in Europe, Raising Match Rates Without Compromising Compliance3.11.2026 09:02:00 CET | Press release

In a five-market pilot, Match Booster beat a global media company’s existing onboarding provider in every head-to-head test, matching 15%+ more people on average and up to 90% more in a single test. Hightouch, the leading agentic marketing platform, today launched Match Booster in the UK, Germany, France, Spain, and Italy. Match Booster helps brands, agencies, media networks, and publishers reach more of their customers on more than 50 ad platforms, including Google, Meta, Amazon, TikTok, and The Trade Desk, by adding to their consented first-party data instead of replacing it. Until now, European advertisers have had two options. They could send first-party data to ad platforms alone and accept the match rates they got. Or they could hand it to a traditional onboarding provider that swaps it for a proprietary ID and drops any customer its graph can’t find, sometimes leaving audiences smaller than they started. Global companies also end up running separate US and EU workflows to meet d

Building on Netherlands NextGen Momentum, Trilliant Showcases Why the Next Generation of AMI is Being Defined by Choice at Enlit Europe 20263.11.2026 09:00:00 CET | Press release

Trilliant highlights how open, interoperable technologies help utilities modernize, protect investments, and preserve long-term flexibility Trilliant, a technology platform partner enabling utilities to gain real-time visibility and optimize performance across an increasingly dynamic energy landscape, will showcase its Power of Choice approach at Enlit Europe 2026, taking place 10–12 November in Vienna, Austria. The company will highlight how intelligent software and device-independent technologies help utilities modernize infrastructure and prepare for evolving grid demands. Trilliant’s participation at Enlit Europe follows its recent selection by Dutch distribution system operators to support the Netherlands’ NextGen smart metering programme. Trilliant’s role includes developing and delivering gateways supported by its transformed UnitySuite® platform, which will be demonstrated during the conference. At Enlit Europe, Trilliant will spotlight its Power of Choice approach, enabling ut

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye